NCNA NuCana plc IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1709626 · Reporting currency GBP · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: GBP | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | 12.74M | 18.02M | 25.06M | 36.43M | 36.83M |
| Operating income | -20.11M | -22.81M | -32.78M | -39.12M | -47.91M |
| Interest expense | 12.65M | 0 | 0 | — | — |
| Pretax income | -30.52M | -22.45M | -32.03M | -38.45M | -47.80M |
| Income tax | -1.17M | -3.45M | -4.40M | -6.43M | -7.27M |
| Net income | -29.35M | -19.00M | -27.63M | -32.02M | -40.53M |
| EBITDA | -19.84M | -22.29M | -32.21M | -38.39M | -46.96M |
| EPS (basic) | 0.00 | -0.26 | -0.53 | -0.61 | -0.78 |
| EPS (diluted) | 0.00 | -0.26 | -0.53 | -0.61 | -0.78 |
| Balance sheet | |||||
| Cash & equivalents | 24.25M | 6.75M | 17.23M | 41.91M | 60.26M |
| Receivables | 849,000 | 922,000 | 2.67M | 3.96M | 4.16M |
| Current assets | 26.86M | 12.27M | 25.02M | 54.92M | 71.61M |
| PP&E, netmay include right-of-use assets (IFRS) | 658,000 | 197,000 | 521,000 | 866,000 | 851,000 |
| Intangibles | 2.20M | 2.20M | 2.13M | 2.37M | 2.41M |
| Total assets | 29.83M | 14.77M | 27.81M | 58.25M | 77.47M |
| Current liabilities | 4.79M | 8.67M | 12.68M | 19.31M | 11.72M |
| Total liabilities | 5.51M | 8.82M | 12.92M | 19.75M | 11.93M |
| Shareholders' equity | 24.33M | 5.95M | 14.89M | 38.50M | 65.55M |
| Cash flow statement | |||||
| Operating cash flow | -7.47M | -19.12M | -26.44M | -23.16M | -23.82M |
| Capital expenditure | 0 | 4,000 | 4,000 | 12,000 | 64,000 |
| Free cash flow | -7.47M | -19.12M | -26.44M | -23.17M | -23.89M |
| Investing cash flow | 159,000 | 79,000 | 2.89M | 120,000 | -3.56M |
| Financing cash flow | 25.01M | 8.18M | -53,000 | -161,000 | -98,000 |
| Depreciation & amortization | 274,000 | 522,000 | 575,000 | 732,000 | 942,000 |
| Stock-based compensation | 10.03M | 1.65M | 3.86M | 4.89M | 6.66M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, GBP, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.